Andrea Rivas
About
Andrea Rivas is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Endocrinology, Diabetes and Metabolism.
According to data from OpenAlex, Andrea Rivas has authored 20 papers receiving a total of 375 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Cardiology and Cardiovascular Medicine, 10 papers in Surgery and 6 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Andrea Rivas's work include Antiplatelet Therapy and Cardiovascular Diseases (15 papers), Lipoproteins and Cardiovascular Health (8 papers) and Diabetes Treatment and Management (5 papers). Andrea Rivas is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (15 papers), Lipoproteins and Cardiovascular Health (8 papers) and Diabetes Treatment and Management (5 papers). Andrea Rivas collaborates with scholars based in United States, Italy and Austria. Andrea Rivas's co-authors include Dominick J. Angiolillo, Latonya Been, Francesco Franchi, Fabiana Rollini, Siva Suryadevara, Martin M. Zenni, Daniel Soffer, Theodore A. Bass, Andrés M. Pineda and Zubair Shaikh and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and Thrombosis and Haemostasis.
In The Last Decade
Andrea Rivas
18 papers receiving 368 citations
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Andrea Rivas United States | 10 | 301 | 152 | 75 | 61 | 18 | 20 | 375 | ||
| Olivier Barthélemy France | 10 | 348 1.2× | 180 1.2× | 62 0.8× | 65 1.1× | 16 0.9× | 15 | 415 | ||
| Orsolya Rideg Hungary | 9 | 246 0.8× | 152 1.0× | 75 1.0× | 42 0.7× | 19 1.1× | 15 | 348 | ||
| Julie K. Brooks United States | 4 | 234 0.8× | 89 0.6× | 47 0.6× | 63 1.0× | 20 1.1× | 6 | 326 | ||
| Julia Maria Kubica Poland | 5 | 243 0.8× | 352 2.3× | 39 0.5× | 60 1.0× | 9 0.5× | 9 | 542 | ||
| Előd Papp Hungary | 10 | 258 0.9× | 86 0.6× | 81 1.1× | 55 0.9× | 9 0.5× | 18 | 326 | ||
| Rosemary Ecob United Kingdom | 7 | 523 1.7× | 213 1.4× | 199 2.7× | 37 0.6× | 29 1.6× | 7 | 593 | ||
| Jurrien M. ten Berg Netherlands | 6 | 262 0.9× | 124 0.8× | 54 0.7× | 43 0.7× | 10 0.6× | 8 | 276 | ||
| Joanna Sikora Poland | 11 | 380 1.3× | 141 0.9× | 122 1.6× | 20 0.3× | 20 1.1× | 39 | 500 | ||
| Takamichi Ono Japan | 8 | 249 0.8× | 112 0.7× | 34 0.5× | 51 0.8× | 6 0.3× | 11 | 308 | ||
| Murali Kodali United States | 8 | 265 0.9× | 99 0.7× | 89 1.2× | 59 1.0× | 14 0.8× | 12 | 310 |
Countries citing papers authored by Andrea Rivas
Since
Specialization
Citations
This map shows the geographic impact of Andrea Rivas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrea Rivas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrea Rivas more than expected).
Fields of papers citing papers by Andrea Rivas
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Andrea Rivas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrea Rivas. The network helps show where Andrea Rivas may publish in the future.
Co-authorship network of co-authors of Andrea Rivas
This figure shows the co-authorship network connecting the top 25 collaborators of Andrea Rivas. A scholar is included among the top collaborators of Andrea Rivas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrea Rivas. Andrea Rivas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Franchi, Francesco, Fabiana Rollini, Latonya Been, et al.. (2025). PHARMACODYNAMIC EFFECTS OF DIFFERENT TICAGRELOR MAINTENANCE DOSING REGIMENS WITH AND WITHOUT ASPIRIN IN PATIENTS WITH DIABETES MELLITUS: THE OPTIMUS (OPTIMIZING ANTIPLATELET THERAPY IN DIABETES MELLITUS)-7 STUDY. Journal of the American College of Cardiology. 85(12). 912–912.
2.
Ortega‐Paz, Luis, Francesco Franchi, Fabiana Rollini, et al.. (2024). Clopidogrel-Mediated P2Y12 Inhibition According to Renal Function in Patients With Diabetes Mellitus and CAD. JACC Basic to Translational Science. 9(7). 865–876.
3.
Alappattu, Meryl, et al.. (2024). A Survey of Pain and Musculoskeletal Dysfunction Prevalence After Gender-Confirming Surgery of the Urogenital System. PubMed. 48(4). 249–256.
4.
Franchi, Francesco, Luis Ortega‐Paz, Fabiana Rollini, et al.. (2023). Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic cardiovascular disease: a randomised, double-blind, placebo-controlled study.. PubMed. 18(15). 1254–1265.
5.
Ortega‐Paz, Luis, Francesco Franchi, Fabiana Rollini, et al.. (2023). Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study. Thrombosis and Haemostasis. 124(3). 263–273.
6.
Franchi, Francesco, Fabiana Rollini, Luis Ortega‐Paz, et al.. (2023). Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions. 16(20). 2528–2539.
7.
Zhang, Yinxin, et al.. (2023). Acute myocardial infarction following 5-fluorouracil treatment. Journal of Geriatric Cardiology. 20(7). 551–554.
8.
Galli, Mattía, Francesco Franchi, Fabiana Rollini, et al.. (2022). Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy. European Heart Journal - Cardiovascular Pharmacotherapy. 8(7). 728–737.
9.
Franchi, Francesco, Luis Ortega‐Paz, Fabiana Rollini, et al.. (2022). Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor. JACC: Cardiovascular Interventions. 16(1). 36–46.
10.
Galli, Mattía, Francesco Franchi, Fabiana Rollini, et al.. (2022). Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease. Thrombosis and Haemostasis. 122(8). 1341–1351.
11.
Giordano, Salvatore, Francesco Franchi, Luis Ortega‐Paz, et al.. (2022). 1156 CANGRELOR IN PATIENTS WITH CORONARY ARTERY DISEASE PRE-TREATED WITH TICAGRELOR: THE SWITCHING ANTIPLATELET (SWAP)-5 STUDY. European Heart Journal Supplements. 24(Supplement_K).
12.
Franchi, Francesco, Fabiana Rollini, Latonya Been, et al.. (2021). Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease. European Heart Journal - Cardiovascular Pharmacotherapy. 8(5). 452–461.
13.
Franchi, Francesco, Dmitry Yaranov, Fabiana Rollini, et al.. (2021). Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study. BMJ Open Diabetes Research & Care. 9(1). e001939–e001939.
14.
Franchi, Francesco, Fabiana Rollini, Andrea Rivas, et al.. (2020). Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes. JACC Basic to Translational Science. 5(5). 419–428.
15.
Ríos, José, et al.. (2019). AN UNCOMMON CAUSE OF INFECTIVE ENDOCARDITIS. Journal of the American College of Cardiology. 73(9). 2572–2572.
16.
Franchi, Francesco, Fabiana Rollini, Andrea Rivas, et al.. (2019). Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation. 139(14). 1661–1670.
17.
Franchi, Francesco, Fabiana Rollini, Andrea Rivas, et al.. (2019). Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study. Thrombosis and Haemostasis. 120(1). 83–93.
18.
Cavallari, Larisa H., Francesco Franchi, Fabiana Rollini, et al.. (2018). Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. Journal of Translational Medicine. 16(1). 92–92.
19.
Franchi, Francesco, Fabiana Rollini, Andrea Rivas, et al.. (2018). Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease. Circulation. 137(23). 2450–2462.
20.
Modak, Brenda, et al.. (2012). Antiviral activity in vitro and in vivo of natural flavonoids isolated from Heliotropium sinuatum against infectious salmon anemia virus (ISAV). Boletin Latinoamericano y del Caribe de plantas Medicinales y Aromaticas. 11(4). 377–384.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Olivier Barthélemy Breakdown of academic impact, for papers by Orsolya Rideg Breakdown of academic impact, for papers by Julie K. Brooks Breakdown of academic impact, for papers by Julia Maria Kubica Breakdown of academic impact, for papers by Előd Papp Breakdown of academic impact, for papers by Rosemary Ecob Breakdown of academic impact, for papers by Jurrien M. ten Berg Breakdown of academic impact, for papers by Joanna Sikora Breakdown of academic impact, for papers by Takamichi Ono Breakdown of academic impact, for papers by Murali Kodali